ACELYRIN Inc reports results for the quarter ended December 31 - Earnings Summary

• ACELYRIN Inc SLRN.OQ reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -97 cents. The mean expectation of three analysts for the quarter was for a loss of 86 cents per share. Wall Street expected results to range from $-1.03 to -67 cents per share.

• Reported revenue was zero​; analysts expected zero.

• ACELYRIN Inc's reported EPS for the quarter was a loss of 79 cents​.

• The company reported a quarterly loss of $79.03 million.

• ACELYRIN Inc shares had fallen by 11.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ACELYRIN Inc is $8.00

This summary was machine generated from LSEG data March 20 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)